Infinion CX Spinal Cord Stimulator Lead Recall

Updated September 9, 2026. The Food and Drug Administration announced a recall involving the Boston Scientific Infinion CX spinal cord stimulator lead on September 3, 2026. Many people searching for spinal cord stimulator recall Infinion CX updates want to know what this means for day‑to‑day safety, function, and the next clinic visit. This page summarizes what the FDA notice covers and offers practical, non‑urgent, safety‑focused questions you can bring to a pain‑clinic appointment for coordinated evaluation and monitoring. The recall itself and any next steps are managed through clinician oversight in collaboration with the manufacturer and the FDA’s device‑safety process [2, 3].

What the September 2026 FDA recall covers

According to the FDA, the Infinion CX lead is a component used with Boston Scientific spinal cord stimulation systems. The agency has posted a recall notice stating the manufacturer is removing the Infinion CX lead from distribution, and the recall is categorized under the FDA’s device‑recall framework for significant safety concerns. The linked FDA database entry lists the action as a Class I device recall specific to Infinion CX leads, which is the most serious recall classification because of the potential risk of harm if the issue occurs [2, 1, 3].

A key point in any FDA device recall is that the action can include different steps such as removing unused inventory, updating labeling or instructions, quality corrections, and post‑market surveillance. A recall does not automatically mean that all implanted devices are removed. Recommendations for people who already have the device depend on the specific issue, individual risk, and clinician assessment. FDA recall communications explain the problem, identify affected products, outline manufacturer actions, and describe how patients and clinicians can coordinate follow‑up and report device problems through MedWatch if needed [3, 2].

What this may mean if you already have an Infinion CX lead

Spinal cord stimulation uses thin leads placed in the epidural space to deliver electrical pulses that can help manage certain patterns of back and leg pain. Like any implanted system, SCS therapy has known device‑related risks that are not unique to this recall. Commonly discussed issues include lead migration or fracture, changes in stimulation coverage, pocket or lead‑track discomfort, infection, and, rarely, neurologic injury. When symptoms arise, evaluation may involve clinical examination, device interrogation and programming review, and, when appropriate, imaging and multidisciplinary coordination to optimize function and safety [4, 5].

Emergency warning signs—go to the emergency department now

Fever with spreading redness or drainage from the implant site. Go to the nearest emergency department or call emergency services now [4].
New or rapidly progressive weakness, numbness, or trouble walking. Go to the nearest emergency department or call emergency services now [4].
New bladder or bowel dysfunction — seek immediate emergency care or call 911 or saddle numbness — seek immediate emergency care or call 911. Go to the nearest emergency department or call emergency services now [4].
Sudden severe back pain with new neurologic deficits. Go to the nearest emergency department or call emergency services now [4].

Non‑urgent, safety‑focused questions to bring to your next pain‑clinic visit

Can you confirm whether my implanted lead model is Infinion CX and whether it is included in the FDA recall? If yes, what information from the operative report, device card, or manufacturer can clarify the specifics for my case? [2, 3]
What monitoring steps are appropriate for someone who feels their stimulation is working acceptably right now, such as scheduled device interrogations, stim‑coverage checks, skin and pocket checks, or documentation of any changes over time? [5]
If I notice changes in stimulation (for example, sudden loss of coverage, unexpected jolts, or new discomfort along the lead path), what should I document and how soon should I request a device evaluation? What findings would prompt same‑day or urgent assessment? [4, 5]
Are there any manufacturer field actions, labeling updates, or programming recommendations relevant to my system that you will incorporate into our follow‑up plan? How will you coordinate with the device representative? [2, 3, 5]
If imaging is considered, which modality best answers the clinical question for lead position or pocket evaluation, and how do we balance benefits and risks in my situation? [4, 5]
How should I track symptoms, activities, and device use between visits so we can make data‑informed decisions about safety and function? [5]
If I experience a device problem, how do we report it to FDA MedWatch, and what information should be included in that report? Does reporting affect my care plan? [3]
If adjustments, revision, or alternative strategies are discussed, how will decisions be coordinated among the implanting surgeon, pain‑management team, and device manufacturer to keep safety first? [5]

How FDA device recalls, early alerts, and patient reporting work

The FDA’s device‑safety program posts Medical Device Recalls and Early Alerts so clinicians and the public can see the concern, affected product identifiers, and recommended actions. These communications are updated as new information becomes available. In addition to manufacturer and clinician reporting, patients may submit problem reports through the FDA’s MedWatch program. A report typically includes the device name and model, a description of what happened, any medical or surgical interventions that followed, and outcomes. Reporting helps the FDA and manufacturers monitor post‑market performance and does not replace individualized clinical care or shared decision‑making about next steps [3].

Context about spinal cord stimulation care and follow‑up

Responsible spinal cord stimulation care centers on function, safety, and realistic expectations. Consensus guidance emphasizes structured follow‑up, systematic troubleshooting of stimulation coverage and hardware concerns, collaboration with manufacturer representatives, and timely consideration of alternative strategies if goals are not being met. In the setting of a recall, those same principles apply, with extra attention to documentation and device surveillance. Programming, lead placement assessment, and multidisciplinary review are coordinated to optimize patient safety while avoiding unnecessary interventions [5, 4].

Limitations, uncertainty, and what may change next

A recall classification signals that a potential risk has been identified, but it does not predict what will happen for any individual. People with the same model may have different clinical courses depending on their anatomy, underlying condition, procedure details, and device use. FDA communications and manufacturer field actions can evolve as more data emerge. As of September 2026, the FDA has posted a Class I recall entry for Infinion CX leads and a separate recall and early‑alerts page that may receive updates. Clinician‑directed monitoring and shared decision‑making remain the cornerstone of safe care while new information develops [1, 2, 3].

How CMS Pain Management & Rehab coordinates recall‑aware spine care

At CMS Pain Management & Rehab, our role is to keep spine‑pain care focused on safety, function, and mobility while staying current with FDA and manufacturer communications. For people living with an implanted spinal cord stimulator, we coordinate with the implanting surgeon, device representatives, and your broader care team to review recall information, align follow‑up intervals, document device performance, and address comfort and rehabilitation goals. When questions arise, we prioritize clear education, structured monitoring plans consistent with consensus guidance, and timely evaluation of any new symptoms—especially those that suggest infection or neurologic change. Do not change medications, device settings, or therapy on your own; these decisions are clinician‑led. Medication decisions, if relevant, are made by the prescribing clinician; device programming or revision decisions are made through clinician‑led discussions that incorporate your preferences and up‑to‑date safety information [5, 3, 4].

FAQs about the spinal cord stimulator recall Infinion CX

Does a Class I recall mean my Infinion CX lead must be removed?

A Class I designation means the FDA believes there is a reasonable chance that use of the device could cause serious health problems if the identified issue occurs. A Class I label does not, by itself, require that all implanted devices be removed. FDA recalls can involve removing unused inventory, updating instructions, and enhanced monitoring, with individualized plans for people who already have the device [3].

What did the FDA announce about the Infinion CX lead recall?

The FDA has posted a notice indicating that Boston Scientific is removing the Infinion CX lead from distribution under the device‑recall framework. The agency’s recall database lists a Class I entry specific to Infinion CX leads. The notice explains the affected product and manufacturer actions, and it may be updated as new information emerges [2, 1, 3].

What symptoms could suggest a problem with a spinal cord stimulator lead?

Loss of expected stimulation coverage, unexpected jolts or shocks, new pain along the lead path or in the device pocket, wound redness or drainage, fever, or new neurologic changes can signal a device or clinical issue that merits evaluation. If you have sudden, severe back pain with new weakness, numbness, saddle numbness — seek immediate emergency care or call 911, or changes in bladder or bowel function, go to the nearest emergency department or call emergency services now [4].

How do I report a problem with my device to the FDA?

Patients and caregivers can submit problem reports to the FDA through MedWatch. A report usually includes the device name and model, what happened, any medical interventions, and outcomes. Reporting supports post‑market surveillance and complements, but does not replace, individualized clinical evaluation and follow‑up planning [3].

Sources

When to Talk With a Clinician

For non-emergency questions, contact CMS Pain Management & Rehab to discuss your symptoms and care options with a qualified clinician. For emergency warning signs, call 911 or seek emergency care now rather than contacting the clinic.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Treatment options, risks, and eligibility vary; consult a qualified healthcare professional.

Infinion CX Spinal Cord Stimulator Lead Recall: What Patients Should Know Now